This is a one year study comparing once a week subcutaneous long acting growth hormone with once a day growth hormone currently available commercially. All eligible subjects will be newly diagnosed, medically untreated growth hormone deficient children who have not yet entered puberty. A 2:1 randomization ratio will be used for the Transcon hGH treatment cohort and the daily rhGH treatment cohort, respectively. 150 subjects will be enrolled study-wide This study will be conducted in approximately 100 trial sites in approximately 20 countries in North and South America, Europe, Middle East and North Africa, and Oceania.
This study is providing annual blood tests looking at diabetes autoantibodies for first degree relatives of patients diagnosed with type 1 diabetes who are between the ages of 1 and 45. It will also provide "diabetes screening" for second and third degree relatives age 1-20. Often parents and/or relatives wonder "if they will get diabetes" down the road or if additional offspring are "at risk" for type 1 diabetes. This study aims at assisting families with free blood testing. If positive, participants will be eligible for "prevention studies". MUSC is currently only participating in the "screening or Natural History" portion of TrialNet.